Survival of Patients with Advanced Lung Cancer Treated with CIMAvax-EGF®

Authors

Keywords:

lung cancer, CIMAvax-EGF, survival.

Abstract

Introduction: The national biotechnology industry has developed therapies directed at the epidermal growth factor receptor, and one of them is the CIMAvax-EGF vaccine as an active immunotherapy that is directly related to increasing overall survival.

Objective: To estimate the survival of patients with advanced lung cancer treated with CIMAvax-EGF.

Methods: A retrospective observational cohort study was carried out at María Curie Oncological Teaching Provincial Hospital in Camagüey province from 2016 to 2018. The universe consisted of 32 patients who had received chemotherapy with unsatisfactory evolution, where they were treated with Cimavax-EGF and followed up in the oncology medicine consultation. The primary source of information was the individual medical record of each patient. The data were processed using Statistical Package for Social Sciences (SPSS) version 26.0.

Results: Patients aged 70 to 79 years, male, with the histological subtype squamous cell carcinoma and clinical stages IIIB and IVA predominated. Overall and progression-free survival was 12.4 and 6.7 months in that order. The predominant response to first-line treatment was partial remission and the most frequent adverse reaction recorded in immunized patients was pain at the injection site.

Conclusions: In patients who had complete response to the first line of treatment, the probability of survival improved when receiving maintenance treatment with CiMAvax-EGF vaccine.

Downloads

Download data is not yet available.

Author Biographies

Juan Ariel Oliva Diaz, Universidad de Ciencias Medicas Carlos J Finlay Hospital Provincial Docente Oncológico “María Curie”

Especialista de primer grado en Medicina General Integral, Especialista de 1er grado en Oncología

Alfredo Enrique Arredondo Rubido, Policlínico Docente Joaquín de Agüero y Agüero

Especialista de 1er grado en Medicina General Integral. Aspirante a investigador

Downloads

Published

2024-02-16

How to Cite

1.
Oliva Diaz JA, Arredondo Rubido AE. Survival of Patients with Advanced Lung Cancer Treated with CIMAvax-EGF®. Rev Cubana Med [Internet]. 2024 Feb. 16 [cited 2025 Mar. 12];63. Available from: https://revmedicina.sld.cu/index.php/med/article/view/3423

Issue

Vol. 63 (2024): publicación continua

Section

Original articles

License

The Cuban Journal of Medicine protects the author's patrimonial rights. However, it is licensed under a Creative Commons Licensehttps://creativecommons.org/licenses/by-nc/4.0/deed.es_ES which permits unrestricted non-commercial use, distribution and reproduction in any medium, provided that the primary source of publication is duly cited. The author always retains his moral rights.

 

You are free to:

- Share - copy and redistribute the material in any medium or format.

- Adapt - remix, transform and build upon the material

- The license cannot revoke these freedoms as long as you follow the terms of the license.

Under the following terms:

- Attribution - You must give proper credit, provide a link to the license, and indicate if changes have been made. You may do so in any reasonable manner, but not in such a way as to suggest that you or your use is supported by the licensor.

- Non-Commercial Purpose- You may not make use of the material for commercial purposes.

- No Additional Restrictions - You may not apply legal terms or technological measures that legally restrict others from making any use permitted by the license.